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Acute Coronary Syndromes
Management and Secondary Prevention
Peter Wenaweser, Stephan Windecker1
Zusammenfassung
Das akute Koronarsyndrom umfasst ein breites Spek-
trum myokardialer Ischämien, die von der instabilen 
Angina pectoris über den Nicht-ST-Hebungsinfarkt bis 
zum akuten ST-Strecken-Hebungsinfarkt reichen. Aku-
te Koronarsyndrome stellen die häufigste Ursache für 
kardial bedingte Hospitalisationen dar. Die rasche Dia-
gnose sowie Risikostratifizierung sind für die Einlei-
tung der optimalen medikamentösen und invasiven 
Behandlung von großer Bedeutung. Therapeutische 
Maßnahmen umfassen potente antiischämische und 
antithrombotische Substanzen sowie eine rasche und 
wirkungsvolle Inhibition der Blutplättchenaggrega-
tion. Darüber hinaus profitieren Patienten mit er-
höhtem Risiko, wie beispielsweise troponinpositive 
Patienten, Patienten mit ST-Strecken-Senkungen sowie 
Diabetiker, von einer frühen invasiven Abklärung. Mo-
difikationen des Lebensstils sowie von Risikofaktoren 
komplementieren die langfristige medikamentöse 
Therapie, um das Rezidivrisiko zu minimieren.
Akutes Koronarsyndrom. Management und Sekundärprävention
Abstract
Acute coronary syndromes represent a broad spec-
trum of ischemic myocardial events including un-
stable angina, non-ST elevation myocardial infarc-
tion and acute ST elevation myocardial infarction, 
which are associated with high morbidity and mor-
tality. They constitute the most frequent cause of 
hospital admission related to cardiac disease. Early 
diagnosis and risk stratification are essential for ini-
tiation of optimal medical and invasive manage-
ment. Therapeutic measures comprise aggressive 
antiplatelet, antithrombotic, and anti-ischemic 
agents. In addition, patients with high-risk features, 
notably positive troponin, ST segment changes and 
diabetes, benefit from an early invasive as compared 
to a conservative strategy. Importantly, lifestyle in-
terventions, modification of the risk factor profile, 
and long-term medical treatment are of pivotal im-
portance in reducing the long-term risk of recur-
rence.
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Introduction
Acute coronary syndromes (ACS) represent a wide 
spectrum of ischemic myocardial events ranging from 
unstable angina (UA) over myocardial infarction (MI) 
to sudden death. The common pathophysiological sub-
strate is coronary thrombosis following rupture or ero-
sion of an atherosclerotic plaque causing ischemia in 
the corresponding myocardial area [1]. The extent of 
intracoronary thrombosis and distal embolization de-
termines the clinical presentation ranging from UA 
without myocardial necrosis over non-ST segment ele-
vation (NSTEMI) to ST segment elevation myocardial 
infarction (STEMI; Table 1). Diagnosis and risk strati-
fication of ACS are based on history, electrocardio-
graphic changes, and cardiac biomarkers [2]. The pres-
ent overview deals with the management of patients 
with NSTE-ACS (UA and NSTEMI).
Diagnosis and Risk Stratification
With over 2.5 million annual hospitalizations world-
wide, ACS account for the most common cause of hos-
pital admission for cardiac disorders, and 50% of coro-
nary care unit admissions. The number of hospitaliza-
tions for NSTE-ACS continues to rise, whereas the 
number of STE-ACS stabilizes or even declines.
Clinical Presentation
Patients with NSTE-ACS usually present with one of 
four clinical patterns:
(1) rest angina of prolonged duration (> 20 min),
(2)  new-onset (de novo) severe angina of at least CCS 
(Canadian Cardiovascular Society) class III,
(3)  accelerating angina of previously diagnosed stable 
angina that has become more frequent, longer in 
duration, or lower in threshold,
(4) post-MI angina.
Patients with NSTE-ACS usually experience angina at 
rest (80%), whereas de novo or accelerated angina is 
observed in 20%. The duration and intensity of angina 
are graded according to the CCS classification (CCS I–
IV). The initial patient evaluation aims at determining 
the likelihood that signs and symptoms are related to 
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obstructive coronary artery disease. The most impor-
tant predictors of ischemia due to coronary artery dis-
ease are summarized in Table 2.
Physical Examination
Physical examination in a patient with suspected ACS 
is frequently normal. A high risk of adverse clinical out-
come is present in patients with hemodynamic instabil-
ity, the presence of pulmonary edema, or an S3 heart 
sound, and a new or increasing mitral regurgitation 
murmur. Physical examination is directed to the exclu-
sion of extracardiac chest pain causes such as pericardi-
tis, pneumothorax and aortic dissection, and search for 
signs of hemodynamic instability and left ventricular 
dysfunction.
Electrocardiography
Electrocardiography allows for classification into STE-
MI and NSTEMI and should be obtained within 10 min 
upon arrival in the emergency room (Figure 1). ST seg-
ment depression with or without T wave changes are 
the most characteristic ECG findings in NSTE-ACS 
patients [3]. ST segment depression as little as 0.05 mV 
is a predictor of adverse outcome with increasing sever-
ity of ST segment depression translating into progres-
sively increased risk. Widespread ST segment depres-
sion in more than six leads is highly specific for acute 
MI as is intermittent ST segment elevation. Deep and 
symmetric T wave inversion in leads V2–V4 usually sug-
gests ischemia caused by a proximal lesion of the left 
anterior descending artery. ST segment depression in 
leads V1–V3 may reveal a true posterior infarction, 
which should be approached like a STEMI. Of note, a 
normal ECG does not exclude the possibility of an 
ACS, since 1–6% of such patients are subsequently 
found to have acute MI as evidenced by elevated bio-
markers.
Nonspecific ST segment and T wave changes, de-
fined as ST segment depression of < 0.05 mV or T wave 
inversion of < 0.2 mV are less diagnostic for acute isch-
emia. In addition, alternative causes for ST segment and 
T wave abnormalities ought to be considered such as 
left ventricular hypertrophy, pericarditis, myocarditis, 
early repolarization, electrolyte imbalances, metabolic 
disorders, digitalis effect, tricyclic antidepressants, phe-
nothiazines, and central nervous system pathologies.
A resting twelve-lead ECG does not reflect the dy-
namic nature of coronary thrombosis in patients with 
ACS. Thus, up to two thirds of ischemic episodes in 
ACS patients remain clinically silent without associated 
chest discomfort. Continuous twelve-lead ECG moni-
toring studies have shown that 15–30% of ACS patients 
have transient episodes of ST segment depression, 
which are associated with adverse outcome. Accord-
ingly, continuous ST segment monitoring adds diag-
nostic and prognostic information in ACS patients.
Biochemical Markers of Myocardial Injury
MI is diagnosed when blood levels of sensitive and spe-
cific markers (troponins T and I, CK-MB [myocardial 
type of creatine kinase]) are increased in the clinical 
setting of acute ischemia. Elevated cardiac biological 
markers without signs of acute ischemia should prompt 
the search for alternative causes of cardiac damage 
such as trauma, pulmonary embolism, hypertensive cri-
sis, myocarditis, etc., since these markers indicate myo-
cardial damage without shedding light on its mecha-
nism. Importantly, no current marker is detectable im-
mediately upon onset of MI and therefore requires 
repeated measurements during the first 6–12 h after ad-
mission (Figure 2).
Troponin has become the preferred biomarker for 
assessment of myocardial damage due to its high car-
diac specificity and sensitivity. Troponins T and I are 
detectable in blood within 4–12 h after the onset of MI, 
and peak values are observed at 12–48 h. Since tropo-
nin levels may stay elevated for 7–10 days after myocar-
dial necrosis, the attribution of cardiac troponin levels 
to other than recent clinical events proves difficult. A 
Type Symptoms ECG Myocardial  Coronary lesion Acute treatment Prognosis
   necrosis
UA Recurrent chest pain  No ST elevation None Severe stenosis Aspirin Reinfarction
 < 20 min ST depression  Small thrombus Clopidogrel Recurrent
  T wave inversion   Thrombin inhibitors ischemia
NSTEMI Recurrent chest  No ST elevation Minor Partial thrombotic Aspirin Reinfarction
 pain < 20 min ST depression  occlusion with or without Clopidogrel Recurrent
  T wave inversion  distal embolization or  Thrombin inhibitors ischemia
    severe stenosis GP IIb/IIIa antagonists
     Early revascularization
STEMI Severe chest pain  ST elevation Large Total and persistent Immediate reperfusion Reinfarction
 > 20 min duration LBBB  thrombotic occlusion Primary PCI Heart failure
  New Q wave   Thrombolysis Arrhythmias
Table 1. Acute coronary 
syndromes. GP: glycopro-
tein; LBBB: left bundle 
branch block; NSTEMI: 
non-ST elevation myo-
cardial infarction; PCI: 
percutaneous coronary 
intervention; STEMI: ST 
elevation myocardial in-
farction; UA: unstable 
angina.
Tabelle 1. Akutes Koro-
narsyndrom. GP: Glyko-
protein; LBBB: Links-
schenkelblock; NSTEMI: 
Nicht-ST-Strecken-He-
bungsinfarkt; PCI: perku-
tane Koronarinterven-
tion; STEMI: ST-Strecken-
Hebungsinfarkt; 
UA: instabile Angina pec-
toris.
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positive troponin test increases the risk of death two- to 
ninefold, and the risk of death or MI two- to fourfold 
compared with troponin-negative patients [4]. Tropo-
nin-positive patients derive the greatest benefit from an 
early invasive strategy with revascularization (40% re-
duction in recurrent cardiac events) and use of GP IIb/
IIIa antagonists (50% reduction in recurrent cardiac 
events). Several other biomarkers have been associated 
with NSTE-ACS including high-sensitive CRP and na-
triuretic peptides such as B-type natriuretic peptide 
(BNP) or its prohormone fragment (NT-proBNP). As 
markers of inflammation and neurohumoral activation, 
they provide prognostic information and may help to 
differentiate patients with chest pain and dyspnea.
Risk Stratification
Risk stratification represents an essential tool to per-
form triage, to select the site of care, to define best 
medical treatment, and to decide upon an invasive 
strategy. In clinical practice, a risk stratification score 
has to be simple and easily assessable. The GRACE 
risk score [5] implements relevant clinical, electrocar-
diographic and laboratory variables and is recommend-
ed as the preferred classification besides the TIMI risk 
score [6], which is simpler to calculate but provides less 
predictive power.
Treatment of NSTE-ACS Patients
The primary goal of the initial treatment in patients 
with NSTE-ACS is the restoration of coronary blood 
flow and resolution of ischemia. The four pillars of 
acute treatment for patients with NSTE-ACS consist 
of:
(1) antiplatelet agents,
(2) anticoagulants,
(3) anti-ischemic therapy,
(4) coronary revascularization
and are summarized in Figure 3.
Antiplatelet Agents
Aspirin. Aspirin inhibits platelet cyclooxygenase-1 
(COX-1) by irreversible acetylation preventing the for-
mation of thromboxane A2, and thus reducing platelet 
aggregation and the likelihood of arterial thrombi for-
mation. Aspirin reduces the relative risk of death by 
15%, and of nonfatal MI by 30% both in acute ischemic 
syndromes and during secondary prevention (Figure 4) 
[7–9]. The benefit of aspirin is present over a wide range 
of doses, whereas the risk of bleeding appears to be 
dose-dependent. Thus, in the CURE trial, aspirin was 
given in conjunction with clopidogrel in doses ranging 
from 75 to 325 mg, and the risk of bleeding was found to 
be lowest with aspirin doses up to 100 mg [10]. Accord-
ingly, it is recommended to initiate treatment with aspi-
rin with an initial dose of at least 160–325 mg nonen-
teric aspirin followed by long-term maintenance thera-
py with 75–100 mg daily. Aspirin’s ability to reduce 
platelet aggregation is limited due to alternative path-
ways of platelet activation involving adenosine diphos-
phate (ADP), thrombin, and collagen.
Thienopyridines. The thienopyridine derivatives ti-
clopidine and clopidogrel irreversibly bind to the P2Y12 
ADP receptor and thereby inhibit ADP-dependent 
platelet activation. Ticlopidine has been largely re-
placed by clopidogrel due to its more favorable safety 
profile while preserving similar efficacy. Clopidogrel 
has been shown somewhat more effective than aspirin 
to reduce cardiovascular events (9% relative risk re-
duction) in patients with atherosclerotic disease in the 
CAPRIE study without increasing the risk of bleeding 
[11]. More importantly, dual antiplatelet therapy con-
sisting of aspirin and clopidogrel has been shown syner-
gistic in preventing thrombus formation and clinical 
Suspicion of acute coronary syndrome
Persistent
ST elevation
ST-T wave 
changes
STEMI
CK-MB or 
troponin 
Troponin
positive
Troponin
2× negative
Biochemical
markers
ECG
Diagnosis NSTEMI
Working 
diagnosis
Normal or
undetermined
Unstable
angina
Figure 1. Classification 
of acute coronary syn-
dromes based on elec-
trocardiographic and 
biochemical markers 
(modified from [35]).
Abbildung 1. Eintei-
lung des akuten Koro-
narsyndroms anhand 
der EKG-Befunde und 
der Biomarker (modifi-
ziert nach [35]).
Table 2. Clinical symptoms of unstable angina/non-ST elevation myocardial in-
farction suggestive of obstructive coronary artery disease. ACS: acute coronary 
syndrome; MI: myocardial infarction.
Tabelle 2. Symptome bei instabiler Angina pectoris/Nicht-ST-Hebungsinfarkt, die 
auf eine flussbehindernde koronare Herzkrankheit hindeuten. ACS: akutes Koro-
narsyndrom; MI: Myokardinfarkt.
(1) Characteristics of symptoms
 •  Chest or left arm pain, reproducing prior documented angina, relieved 
promptly by nitroglycerin
 •  Atypical chest pain does not exclude the possibility of ACS!
(2) Demographics and prior history
 •  Prior history of MI
(3) Male sex
 •  Male patients are more likely to have obstructive coronary artery disease
(4) Age > 65 years
 •  Increased risk of both underlying coronary artery disease and multivessel 
disease
(5) Number of atherosclerotic risk factors present
 •  Diabetes mellitus
 •  Extracardiac manifestation of atherosclerotic disease
Wenaweser P, Windecker S. Management and Prevention of ACS
28 Herz 33 · 2008 · Nr. 1  © Urban & Vogel
events. Thus, clopidogrel in addition to aspirin reduced 
the relative risk of death, nonfatal MI and stroke by 
20% compared with aspirin alone in NSTE-ACS pa-
tients in the CURE trial (Figure 5) [12]. The beneficial 
effect of clopidogrel was present in all subgroups in-
cluding those with low- and high-risk features, emerges 
within hours of administration and remains durable up 
to 1 year. In CURE, major bleeding occurred more fre-
quently with clopidogrel and aspirin (3.7%) than with 
aspirin alone (2.7%; p < 0.001), particularly in those pa-
tients undergoing coronary artery bypass grafting 
(CABG), but fatal or life-threatening bleeding was 
similar [12]. The therapeutic benefit of dual antiplatelet 
therapy with clopidogrel and aspirin outweighs the in-
creased risk of bleeding in patients with NSTE-ACS, 
but in case of CABG, clopidogrel should be discontin-
ued 5 days before the operation to reduce the risk of 
bleeding.
Analyses of TARGET, PCI-CURE, and CREDO 
suggest that pretreatment with a loading dose of at 
least 300 mg clopidogrel reduces the risk of death 
or MI in patients undergoing percutaneous coronary 
intervention (PCI), particularly when administered 
> 12 h before the intervention [13–15]. A loading dose 
of 600 mg clopidogrel results in even more rapid and 
potent platelet inhibition and may be considered in pa-
tients undergoing an early invasive strategy [16]. In 
summary, NSTE-ACS patients should receive the fol-
lowing regimen:
(1)  an immediate loading dose of 300–600 mg clopido-
grel followed by 75 mg clopidogrel daily in addition 
to aspirin. A loading dose of 600 mg clopidogrel is 
preferred in patients considered for an invasive 
strategy undergoing PCI.
(2)  The maintenance dose of 75 mg of clopidogrel 
should be maintained for the duration of 1 year in 
the absence of an excessive bleeding risk.
(3)  Clopidogrel replaces aspirin in all patients with a 
contraindication to aspirin.
Glycoprotein IIb/IIIa receptor inhibitors. The GP 
IIb/IIIa receptor is an integrin found in the platelet 
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Treatment algorithm of NSTE-ACS patients
Aspirin, clopidogrel 300−600 mg, UFH/enoxaparin/fondaparinux/bivalirudin, β-blocker, nitrates, statin
High risk
− Chest pain > 20 min or ongoing
− Hemodynamic/rhythmic instability
− ST segment depression > 1 mm in > 2 leads
− Troponin positive
− LVEF < 40%
− Diabetes mellitus
Low risk
− No ongoing chest pain
− Nondiagnostic ECG
− Troponin negative
Consider GP IIb/IIIa inhibitor*
in addition to aspirin, clopidogrel
UFH/LMWH/bivalirudin 
Early invasive strategy
2nd troponin measurement
Positive Negative
Stress test
Positive Negative
DischargeCoronaryangiography
Coronary angiography
within 72 h
Medical treatment PCI CABG
Clopidogrel 
in addition to aspirin
With GP IIb/IIIa
inhibitor Stop clopidogrel
Figure 3. Management 
of patients with un-
stable angina/non-ST 
segment elevation 
myocardial infarction. 
*Glycoprotein 
IIb/IIIa inhibitors: tiro-
fiban and eptifibatide 
preferred over abcix-
imab, if started prior 
to coronary angiogra-
phy; abciximab pre-
ferred over tirofiban 
and eptifibatide, if 
started at time of cor-
onary intervention.
Abbildung 3. Behand-
lung von Patienten 
mit instabiler Angina 
pectoris/Nicht-ST-He-
bungsinfarkt. *Glyko-
protein-IIb/IIIa-Inhibi-
toren: Tirofiban und 
Eptifibatid werden ge-
genüber Abciximab 
bevorzugt, falls die Ga-
be vor der Koronaran-
giographie erfolgt; Ab-
ciximab wird gegen-
über Tirofiban und 
Eptifibatid bevorzugt, 
falls die Gabe wäh-
rend der Intervention 
erfolgt.
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membrane and conceived as final common pathway 
of platelet aggregation. Platelet GP IIb/IIIa receptor 
inhibitors are a class of potent antiplatelet agents in-
terfering with this receptor with currently three agents 
available for intravenous administration. Abciximab 
is a monoclonal chimeric antibody, which irreversibly 
binds to the GP IIb/IIIa receptor, whereas tirofiban 
and eptifibatide are synthetic, reversible, small-mole-
cule inhibitors of the GP IIb/IIIa receptor. Overall, 
these agents have shown a modest 1% absolute and 
9% relative reduction of death and nonfatal MI in 
NSTE-ACS patients, that was associated with a 1% 
increase in bleeding complications [17]. In patients 
with renal failure (creatinine clearance < 30 ml/min), 
tirofiban requires dose adaptations, eptifibatide is 
contraindicated, and abciximab has no specific recom-
mendations except for careful monitoring of bleeding 
complications.
NSTE-ACS patients with high-risk features, no-
tably troponin-positive patients, those with ST seg-
ment depression, and diabetic patients (26% relative 
mortality reduction), derive the greatest benefit from 
GP IIb/IIIa receptor inhibitors [18, 19]. Consistent re-
sults have also been obtained in NSTE-ACS patients 
undergoing early revascularization by PCI with a 38% 
relative risk reduction of death and MI (Figure 6) [17]. 
In addition, a meta-analysis reported a significant risk 
reduction in 30-day mortality among 20,186 
NSTE-ACS patients undergoing PCI when GP IIb/
IIIa receptor inhibitors were used [20]. While most of 
the studies were performed prior to the use of thieno-
pyridines, the benefit of abciximab in addition to clop-
idogrel and aspirin was recently confirmed in the 
ISAR-REACT 2 trial [21]. In 2,022 NSTE-ACS pa-
tients pretreated with 600 mg clopidogrel and aspirin, 
abciximab reduced the 30-day risk of death, MI and 
urgent revascularization by 25%, a benefit that was 
particularly pronounced in troponin-positive pa-
tients.
The two small-molecule GP IIb/IIIa receptor in-
hibitors tirofiban and eptifibatide may be used for 
“upstream” therapy, i.e., 1–2 days prior to coronary 
angiography and continued for 24 h after PCI [22–24]. 
By contrast, abciximab is not indicated in patients 
treated conservatively and should be initiated only at 
the time of coronary angiography when the decision 
to proceed with PCI has been made. In a head-to-head 
comparison with tirofiban in standard doses, abcix-
imab was found superior at 30 days but not at 6 months 
[15, 25]. In the recent ACUITY-TIMING trial, a de-
ferred selective administration of GP IIb/IIIa recep-
tor inhibitors did not meet the noninferiority criterion 
compared with their routine upstream use, although 
the increase in ischemic events was statistically not 
significant and limited to revascularization procedures 
rather than other endpoints such as death or MI [26].
In summary, triple antiplatelet therapy with GP 
IIb/IIIa receptor inhibitors in addition to aspirin and 
clopidogrel is indicated in patients with high-risk 
NSTE-ACS undergoing PCI. GP IIb/IIIa receptor in-
hibitors must be combined with an anticoagulant. In 
high-risk patients not pretreated with GP IIb/IIIa re-
ceptor antagonists and undergoing PCI, abciximab is 
preferred over eptifibatide and tirofiban. Conversely, 
in patients treated upstream with GP IIb/IIIa receptor 
antagonists prior to angiography, eptifibatide and tiro-
fiban are preferred over abciximab.
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Figure 4. Beneficial effect of aspirin on incidence of death and myocardial infarc-
tion in NSTE-ACS patients in four randomized trials comparing aspirin with pla-
cebo.
Abbildung 4. Effekt von Aspirin auf Mortalität und Herzinfarkt bei Patienten mit 
Nicht-ST-Hebungsinfarkt in vier randomisierten Studien, welche Aspirin mit Pla-
zebo verglichen haben.
Figure 5. Effect of dual antiplatelet therapy with aspirin and clopidogrel com-
pared with aspirin alone on the combined endpoint of death, myocardial infarc-
tion and stroke in patients with acute coronary syndromes (obtained with per-
mission from [12]).
Abbildung 5. Einfluss der Kombinationstherapie aus Aspirin plus Clopidogrel im 
Vergleich zur Monotherapie mit Aspirin auf den kombinierten Endpunkt Tod, 
Myokardinfarkt und Hirnschlag bei Patienten mit akutem Koronarsyndrom (mit 
Genehmigung aus [12]).
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Resistance to antiplatelet agents and drug-drug interac-
tions. The questions of a clinically relevant resistance or 
low response to antiplatelet drugs and of drug-drug in-
teractions of clopidogrel with statins metabolized by 
cytochrome P450 remain open for the time being. At 
current stage, no routine assessment of platelet aggre-
gation inhibition can be recommended to test response 
to aspirin or clopidogrel. The lack of a uniform defini-
tion of “resistance” and the unknown clinical impact do 
not support routine testing in clinical practice. Further-
more, clopidogrel can be given in combination with any 
statin as there have been no conclusive clinical drug-drug 
interactions reported so far [27]. By contrast, there is 
evidence, that concomitant use of selective COX-2 in-
hibitors and nonselective nonsteroidal drugs in combi-
nation with aspirin or clopidogrel may be associated 
with an increased risk of ischemic events and, therefore, 
the combination of these drugs should be avoided.
Anticoagulants
Unfractionated heparin. Unfractionated heparin 
(UFH), a glycosaminoglycan made of polysaccharide 
chains ranging in molecular weight from 2,000 to 30,000 
Da, exerts its anticoagulant effect by binding to anti-
thrombin and thus inactivates factor Xa and thrombin. 
UFH is administered intravenously and has unpredict-
able pharmacokinetics requiring frequent anticoagula-
tion monitoring. It should be administered as a 
weight-adjusted bolus of 60 IU/kg (maximal dose 4,000 
IU) followed by an infusion of 12 IU/kg/h. Further dos-
ing adjustments are based on measurements of activat-
ed partial thromboplastin time (aPTT, 50–70 s). If add-
ed to aspirin, UFH reduces the relative risk of death 
and MI by 33% and has been standard treatment of pa-
tients with ACS during the past 20 years [28]. UFH also 
exhibits prothrombogenic properties and reactivation 
of the coagulation process is measurable within the 1st 
day after UFH termination. As the anticoagulant effect 
of UFH is rapidly reversed by administration of prot-
amine, due to its low cost, and the fact that it has not to 
be dose-adjusted in patients with renal failure, UFH is 
still widely used during PCI in NSTE-ACS patients.
Low-molecular-weight heparin. Low-molecular-
weight heparins (LMWHs) are obtained by chemical 
and enzymatic depolymerization of the heparin poly-
saccharide chains resulting in short chain fragments 
with a molecular weight ranging from 2,000 to 10,000 
Da. LMWHs have a higher anti-Xa:anti-IIa activity 
than UFH, which provides for more potent inhibition 
of thrombin generation. Compared with UFH, the 
pharmacokinetic profile of LMWHs is more predict-
able with a high bioavailability and long plasma half-life 
without the need to monitor anticoagulation. In addi-
tion, LMWHs result in less platelet activation, a lower 
risk of heparin-induced thrombocytopenia (HIT), and 
can be easily administered by the subcutaneous route.
Dalteparin and nadroparin have been shown 
equally effective and safe as UFH in aspirin-treated 
NSTE-ACS patients [28]. Most evidence in NSTE-ACS 
patients has been generated with the LMWH enoxapa-
rin. In the largest trial comparing UFH with enoxaparin 
(SYNERGY; n = 10,027 patients) with a high propor-
tion of PCI revascularization procedures, stent implan-
tation, and concomitant use of clopidogrel and GP IIb/
IIIa receptor antagonists, enoxaparin showed no bene-
fit in terms of death or MI (14.0% vs. 14.5%; odds ratio 
[OR] = 0.96, 95% confidence interval [CI] 0.86–1.08) at 
30 days, but was associated with an increased risk of 
TIMI major bleeding (9.1% vs. 7.6%; p = 0.008) [29]. A 
meta-analysis of all six trials comparing UFH with 
enoxaparin in 21,946 patients suggested a modest 9% 
relative risk reduction in terms of the combined end-
point of death or MI at 30 days (10.1% vs. 11.0%; OR = 
0.91, 95% CI 0.83–0.99) without a significant difference 
in major bleeding at 7 days (4.7% vs. 4.5%; OR = 1.04, 
95% CI 0.89–1.10) and 30 days (Figure 7) [30]. A 
post-hoc subgroup analysis showed a significant reduc-
tion in death or MI in enoxaparin-treated patients, who 
did not receive UFH prior to randomization (8.0% vs. 
9.4%; OR = 0.81, 95% CI 0.70–0.94) without an in-
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n
p = 0.17
9.7%
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PCI on
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Figure 6. Differential effect of glycoprotein (GP) IIb/IIIa antagonists on the com-
bined endpoint of death and myocardial infarction in relation to revascularization 
therapy. Top: lack of therapeutic benefit exerted by GP IIb/IIIa antagonists in pa-
tients managed conservatively. Middle: lack of therapeutic benefit exerted by GP 
IIb/IIIa antagonists in patients undergoing delayed percutaneous coronary inter-
vention (PCI) after discontinuation of study drug. Bottom: pronounced therapeu-
tic benefit exerted by GP IIb/IIIa antagonists in patients undergoing PCI during 
index hospitalization while on study drug. (Obtained with permission from [17].)
Abbildung 6. Effekt der Glykoprotein-(GP-)IIb/IIIa-Inhibitoren auf den kombi-
nierten Endpunkt Tod und Myokardinfarkt in Abhängigkeit von der Revaskularisa-
tionstherapie. Oben: fehlender therapeutischer Nutzen der GP-IIb/IIIa-Inhibitoren 
bei konservativ behandelten Patienten. Mitte: fehlender therapeutischer Nutzen 
der GP-IIb/IIIa-Inhibitoren bei Patienten mit verzögerter perkutaner Koronarin-
tervention (PCI) nach Absetzen der Studienmedikation. Unten: ausgeprägter the-
rapeutischer Nutzen bei Gabe von GP-IIb/IIIa-Inhibitoren während der PCI. (Mit 
Genehmigung aus [17].)
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creased risk of bleeding. Therefore, it has been sug-
gested that the initially commenced anticoagulant 
(UFH or LMWH) should be continued during and af-
ter PCI to avoid crossover and combination of anti-
thrombotic drugs, which may result in a higher risk of 
bleeding. Enoxaparin has also been shown safe and ef-
fective in patients undergoing PCI in conjunction with 
GP IIb/IIIa receptor antagonists. LMWHs should be 
used with caution in patients with renal insufficiency 
and avoided in the presence of severe renal failure (cre-
atinine clearance < 30 ml/min).
Direct thrombin inhibitors. Direct thrombin inhibitors 
(DTIs) bind directly to thrombin (factor IIa) indepen-
dent of antithrombin and inhibit the conversion of fi-
brinogen to fibrin. In contrast to heparin, DTIs inacti-
vate not only soluble but also fibrin-bound thrombin 
and therefore have an +ffect on existing thrombus. The 
lack of binding to plasma proteins results in a predict-
able anticoagulant effect, which can be monitored by 
measuring aPTT and ACT (activated clotting time). In 
addition, the half-life of DTIs is very short compared 
with UFH and probably responsible for the beneficial 
effect in terms of bleeding complications. DTIs have 
also an effect on platelets by reducing thrombin-in-
duced platelet activation. Univalent DTIs comprise ar-
gatroban, melagatran and dabigatran and bind to the 
active site of thrombin. Bivalent DTIs such as hirudin 
and bivalirudin block both the active site of thrombin 
and exosite 1.
In a meta-analysis of eleven trials comparing var-
ious DTIs with UFH in NSTE-ACS and PCI pa-
tients, DTIs were associated with both, a reduced 
rate of death or MI (4.3% vs. 5.1%; OR = 0.85, 95% 
CI 0.77–0.94; p = 0.001) and major bleeding (1.9% vs. 
2.3%; OR = 0.75, 95% CI 0.65–0.87; p < 0.001) [31]. 
While univalent DTIs showed reduced efficacy com-
pared with UFH, hirudin was associated with a higher 
rate of major bleeding (1.7% vs. 1.3%; OR = 1.28, 95% 
CI 1.06–1.55) compared with UFH. Only bivalirudin 
had a favorable effect on both, efficacy (death or 
MI: 3.5% vs. 4.2%; OR = 0.83, 95% CI 0.61–1.12) and 
safety (bleeding: 4.2% vs. 9.0%; OR = 0.44, 95% CI 
0.34–0.56) compared with UFH.
In the setting of PCI, bivalirudin was superior to 
UFH alone with respect to the combined endpoint of 
death, MI and repeat revascularization (6.2% vs. 7.9%; 
OR = 0.78, 95% CI 0.62–0.99; p = 0.04), while major 
bleeding was significantly reduced. In the REPLACE-2 
study, bivalirudin with provisional use of GP IIb/IIIa 
receptor antagonist was found noninferior to UFH 
combined with GP IIb/IIIa receptor antagonist in terms 
of death, MI or repeat revascularization, while major 
and minor bleedings were significantly reduced [32]. 
The ACUITY trial compared three regimens consist-
ing of UFH/LMWH with GP IIb/IIIa receptor antago-
nist, bivalirudin with GP IIb/IIIa receptor antagonist, 
and bivalirudin alone in 13,819 NSTE-ACS patients at 
moderate to high risk [48]. Three primary endpoints at 
30 days were prespecified including a composite isch-
emia endpoint (death, MI, urgent revascularization), 
major bleeding, and net clinical outcome (combination 
of composite ischemia or major bleeding; Figures 8a to 
8c). Event rates of ischemia (7.4% vs. 7.9%; relative 
risk (RR) = 1.07, 95% CI 0.92–1.23; p = 0.39) and major 
bleeding (5.7% vs. 5.3%; RR = 0.93, 95% CI 0.78–1.10; 
p = 0.38) were similar for the two treatment arms using 
GP IIb/IIIa receptor antagonists regardless of UFH/
LMWH or bivalirudin use. By contrast, bivalirudin 
alone was found noninferior to the two treatment arms 
with GP IIb/IIIa receptor antagonist in terms of isch-
emia (7.8% vs. 7.3%; RR = 1.08, 95% CI 0.93–1.24; p = 
0.32) but significantly better with respect to major 
bleeding (3.0% vs. 5.7%, RR = 0.53, 95% CI 0.43–0.65; 
p < 0.001). Of note, in patients not pretreated with clop-
idogrel prior to PCI, the composite ischemia endpoint 
was more frequent in the bivalirudin alone group com-
pared with UFH/LMWH combined with GP IIb/IIIa 
receptor antagonist (9.1% vs. 7.1%; RR = 1.29, 95% CI 
1.03–1.63) with nearly significant interaction (p = 0.054) 
between pretreatment with clopidogrel and the effect 
of bivalirudin alone, supporting the importance of ade-
quate platelet inhibition prior to PCI. Furthermore, 
41% of patients included in ACUITY were tropo-
nin-negative and therefore at lower risk, which may 
have led to a higher bleeding risk associated with GP 
IIb/IIIa receptor antagonists compared with bivalirudin 
alone without any beneficial effect on ischemia end-
points in these patients. It remains to be determined 
whether upstream treatment with intravenous bivaliru-
din prior to catheterization will find widespread use due 
to the relatively high cost. The infusion dose of bivaliru-
din should be reduced to 1.0 mg/kg/h in patients with 
severe renal failure (creatinine clearance < 30 ml/min) 
and to 0.25 mg/kg/h in patients on hemodialysis.
Factor Xa inhibitors. The only factor Xa inhibitor avail-
able for clinical use is fondaparinux. It is a synthetic 
pentasaccharide, which inhibits factor Xa in directly by 
binding to antithrombin similar to UFH and LMWH. It 
has no activity against thrombin. Fondaparinux is ad-
ministered subcutaneously, has 100% bioavailability 
with an elimination half-life of 17 h. A fixed dose of 2.5 
mg fondaparinux once daily is recommended in 
NSTE-ACS patients without the need for monitoring 
anti-Xa activity. The drug has no measurable impact on 
usual anticoagulant variables including aPTT, ACT, 
and prothrombin time. No case of HIT has been report-
ed in various trials and therefore monitoring of platelet 
counts is not necessary. Since it is eliminated mainly by 
the renal route, fondaparinux is contraindicated in pa-
tients with a creatinine clearance of < 30 ml/min.
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Fondaparinux (n = 233) has been compared with 
UFH (n = 117) in the setting of PCI in a small phase II 
trial (ASPIRE) at doses of 2.5 mg and 5.0 mg and 
showed similar efficacy (composite of death, MI, revas-
cularization: 6.0% vs. 6.0%; hazard ratio [HR] = 1.01, 
95% CI 0.41–2.52; p = 0.97) and safety (bleeding: 6.4% 
vs. 7.7%; HR = 0.81, 95% CI 0.35–1.84; p = 0.61) [33]. 
While catheter thrombi were reported with both UFH 
and fondaparinux, they were more frequent with the 
latter. In the OASIS-5 trial, 20,078 NSTE-ACS patients 
were randomly assigned to treatment with either 
fondaparinux 2.5 mg s.c. once daily or enoxaparin 
1 mg/kg twice daily for a mean of 6 days [34]. 
Fondaparinux was found noninferior to enoxaparin for 
the primary efficacy endpoint, a composite of death, 
MI, or refractory ischemia assessed at 9 days (5.8% vs. 
5.7%; HR = 1.01, 95% CI 0.90–1.13). The rate of major 
bleeding at 9 days was significantly lower with 
fondaparinux than enoxaparin (2.2% vs. 4.1%; HR = 
0.52, 95% CI 0.44–0.61; p < 0.001), which resulted in a 
lower net clinical outcome (composite of efficacy and 
major bleeding in favor of fondaparinux [7.3% vs. 9.0%; 
HR = 0.81, 95% CI 0.73–0.89; p < 0.001]). In addition, 
major bleeding was an independent predictor of mor-
tality, which was significantly reduced at 30 days (2.9% 
vs. 3.5%; HR = 0.83, 95% CI 0.71–0.97; p = 0.02) and 6 
months (5.8% vs. 6.5%; HR = 0.89, 95% CI 0.80–1.00; p 
= 0.05; Figure 9). The explanation for the higher mortal-
ity associated with bleeding remains uncertain, but has 
been related to rebound ischemic events due to activa-
tion of the coagulation cascade, cessation of antithrom-
botic therapy after a bleeding event, or adverse effects 
of hypotension or transfusions. Only 63% of patients in 
OASIS-5 had coronary angiography during hospital-
ization and 34% of patients underwent revasculariza-
tion by PCI. Of note, enoxaparin-treated patients re-
ceived UFH during PCI, if the last dose of enoxaparin 
had been administered > 6 h, a recommendation which 
does not correspond to current guidelines where the 
initial anticoagulant should be continued during PCI. 
Among patients undergoing PCI during hospitaliza-
tion, the primary efficacy endpoint was similar for 
fondaparinux and enoxaparin at 9 days (9.3% vs. 8.6%) 
and 30 days (10.4% vs. 9.6%), but rates of major bleed-
ing within 48 h of the procedure were lower with 
fondaparinux (1.6%) than enoxaparin (3.6%; p < 
0.001). However, catheter thrombosis was more fre-
quently observed in the fondaparinux (0.9%) than the 
enoxaparin (0.3%) group. Therefore, it is recommend-
ed to administer a weight-adjusted bolus of intravenous 
UFH at the time of PCI in order to avoid catheter 
thrombosis without increasing the risk of bleeding.
In conclusion, current guidelines [35] stress the 
need for anticoagulation in addition to antiplatelet 
therapy for all NSTE-ACS patients (I-A). An individu-
al risk assessment of ischemic as well as bleeding events 
should be performed, and the choice of initial treatment 
strategy (conservative vs. invasive) will determine 
which anticoagulant agent is preferred. In case of an ur-
gent invasive strategy, UFH (I-C), enoxaparin (IIa-B), 
or bivalirudin (I-B) should be administered immedi-
ately. In a nonurgent situation with the decision be-
tween an early invasive and conservative strategy pend-
ing, fondaparinux has been recommended over enoxa-
parin (IIa-B) and UFH (IIa-B) on the basis of its more 
favorable safety profile (I-A). During PCI, the initial 
anticoagulant should be maintained in case of UFH 
(I-C), enoxaparin (IIa-B), and bivalirudin (I-B), where-
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Abbildung 7. Auftreten 
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misierten Studien, die un-
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bei Patienten mit Nicht-
ST-Hebungsinfarkt ver-
glichen haben (mit 
Genehmigung aus [30]).
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Figures 8a to 8c. Kaplan-Meier 
event curves for the endpoints 
net clinical outcome (a), com-
posite ischemia (b), and major 
bleeding (c) at 30 days 
(obtained with permission 
from [48]). 
Abbildungen 8a bis 8c. Kaplan-
Meier-Kurven für die End-
punkte klinisches Ergebnis (a), 
Ischämie (b) und schwere Blu-
tung (c) nach 30 Tagen (mit 
Genehmigung aus [48]).
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as a weight-adjusted bolus of intravenous UFH is nec-
essary in case of fondaparinux (IIa-C).
Anti-Ischemic Drugs
-blockers. -blockers decrease myocardial oxygen 
consumption, inhibit the effect of circulating catechol-
amines and relieve ischemic chest pain. They are rec-
ommended in all NSTE-ACS patients in the absence of 
contraindications. -blockers should be used with cau-
tion in patients with heart failure, arterial hypotension, 
asthma, and bradyarrhythmias.
Nitrates. Nitrates cause vasodilatation of veins, arteries 
and arterioles by smooth muscle cell relaxation. They 
augment coronary collateral blood flow, reduce the fre-
quency of coronary vasospasm, and potentially inhibit 
platelet aggregation. Both preload and afterload are 
reduced improving the ratio of oxygen demand to sup-
ply and thus reducing ischemia. As only observational 
data or small studies have been performed, evidence of 
a benefit with respect to hard clinical endpoints like 
death or MI is lacking. Intravenous nitrates are recom-
mended for ongoing ischemic chest pain due to the ease 
of administration, titration and rapid resolution of ef-
fects as soon as the infusion is discontinued. Tolerance 
to nitrate therapy may develop as soon as 24 h after ini-
tiation of therapy and may be overcome by increasing 
the dose or changing the route of administration.
Calcium channel blockers. They have vasodilating ef-
fects on the coronary and peripheral circulation and 
may effectively relieve symptoms. A direct comparison 
of metoprolol with nifedipine favored the use of the 
-blocker [36]. Although there are only sparse and con-
flicting data on the use of calcium channel blockers in 
NSTE-ACS patients, they are useful as treatment op-
tion in patients already receiving -blockers and ni-
trates, in patients with contraindications to -blockers 
and those with vasospastic angina.
Coronary Revascularization in NSTE-ACS 
Patients
Significant coronary artery lesions are present in 
80–90% of patients with ACS. Data from the 
TACTICS-TIMI 18 trial revealed narrowing of the left 
main coronary artery in 9%, single-vessel disease in 
26%, and three-vessel disease in 34% of patients [37]. 
The risk of complications during revascularization 
procedures is higher than in stable patients, and there 
has been a debate about the benefits of routine early 
invasive compared with a noninvasive, conservative 
strategy.
A meta-analysis of seven randomized clinical trials 
comparing routine angiography followed by revascu-
larization with a conservative strategy in NSTE-ACS 
patients showed a reduced rate of death and MI (12.2% 
vs. 14.4%; OR = 0.82, 95% CI 0.72–0.93; p = 0.001) at 
the end of follow-up for routine invasive versus selec-
tive invasive [38]. Similar results were found in another 
meta-analysis of six contemporary trials (Figure 10) 
[35]. However, the overall benefit came at the cost of an 
increased hazard during the initial hospitalization (5.2% 
vs. 3.8%; OR = 1.36, 95% CI 1.12–1.66; p = 0.002), 
whereas the benefit emerged during the period from 
discharge to end of follow-up (7.4% vs. 11.0%; OR = 
0.64, 95% CI 0.55–0.75; p < 0.001). This early risk has 
been reduced in the setting of PCIs with the advent 
of clopidogrel pretreatment and GP IIb/IIIa receptor 
antagonists. A more recent meta-analysis of eight 
NSTE-ACS patient trials extended the above findings 
by reporting a significant 25% relative risk reduction of 
overall mortality at 2 years of follow-up [39]. The 
long-term mortality reduction has also been confirmed 
in the 5-year follow-up of RITA-3 [40] and FRISC-II 
[41]. A linear relationship between the difference in 
rate of revascularization between the invasive and con-
servative treatment arm and the derived mortality ben-
efit has been shown in an analysis of several studies 
comparing a routine invasive with a selective invasive 
strategy. This may explain in part the lack of benefit of 
an early invasive strategy in the ICTUS trial, as a large 
proportion in the conservative arm underwent revascu-
larization (“crossover”) [42]. In addition, the majority 
of MIs in ICTUS (67%; defined as more than one to 
three times the upper limit of normal) were proce-
dure-related with unclear consequences on long-term 
prognosis.
The optimal timing of an early invasive strategy re-
mains uncertain, since the time interval of coronary an-
giography varied from as short as 2.4 h (ISAR-
COOL) [43] to 96 h (FRISC-II) [44] and outcome re-
sults were inconsistent. Notwithstanding, it is anticipated 
that contemporary antiplatelet (clopidogrel, GP IIb/II-
Ia receptor inhibitors) and anticoagulant therapy lower 
the risk of periinterventional ischemic complications 
and therefore an invasive strategy is advised within 24–
72 h of admission. The greatest benefit (> 50% relative 
risk reduction) of an early invasive strategy is observed 
in moderate- to high-risk NSTE-ACS patients, notably 
patients with ST segment depression and/or positive 
troponin test. Current practice guidelines therefore rec-
ommend an early invasive strategy consisting of coro-
nary angiography followed by appropriate revascular-
ization by either PCI or CABG as routine management 
in intermediate- to high-risk NSTE-ACS patients at fa-
cilities with adequately trained staff and appropriate 
equipment (I-A). In addition, an urgent invasive strat-
egy should be entertained in patients with severe, ongo-
ing chest pain, dynamic ST segment changes, malignant 
arrhythmias, and hemodynamic instability (I-C).
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Long-Term Management
Patients with NSTE-ACS have a similar risk of recur-
rent ischemic events as patients with STE-ACS. Life-
style interventions, modification of the risk factor pro-
file, and medical treatment are therefore crucial ele-
ments of long-term management. Lifestyle interventions 
include smoking cessation, regular physical activity, 
and a healthy diet with low salt intake and reduced pro-
portion of saturated fats. Current recommendations of 
physical exercise include 30 min of walking or jogging 
three to seven times per week with the goal to increase 
heart rate to 70% of the predicted maximum. Weight 
reduction is of importance in overweight patients and 
may be combined with physical activity. Secondary 
benefits from meaningful weight reduction are an im-
proved glycemic control, a more favorable lipid profile, 
and better blood pressure control. The goal of weight 
reduction should be a body mass index of < 25 kg/m2 or 
a waist circumference of < 88 cm in women and < 102 
cm in men. Blood pressure control aims at < 140/90 
mmHg in nondiabetic patients and < 130/80 mmHg in 
patients with diabetes or chronic renal dysfunction. 
Glycemic abnormalities should be actively assessed in 
NSTE-ACS patients, and in patients with established 
diabetes, an HbA1c level < 6.5% should be achieved.
Medical treatment with statins is a cornerstone of 
secondary prevention in all patients with established 
coronary artery disease across all subgroups regardless 
of baseline cholesterol levels. A meta-analysis of 13 tri-
als in 17,963 patients attested to the safety of early statin 
therapy initiation and a significant reduction of isch-
emic events at 2 years of follow-up [45]. Current guide-
lines recommend combined dietary and pharmacologi-
cal interventions to reduce LDL to < 100 mg/dl (< 2.6 
mmol/l) initiated early (within 1–4 days) after admis-
sion. An even more aggressive reduction of LDL cho-
lesterol among NSTE-ACS patients has been investi-
gated in the PROVE-IT study comparing a regimen of 
80 mg atorvastatin with 40 mg pravastatin [46]. Inten-
sive lipid lowering resulted in a 16% relative risk reduc-
tion of death, MI, revascularization, or stroke, and the 
difference began to emerge after only 3 months.
-blockers improve prognosis following NSTE-
ACS by reducing mortality, reinfarction, and symptoms 
of angina and should be continued particularly in pa-
tients with reduced left ventricular function. Angioten-
sin-converting enzyme (ACE) inhibitors reduce mor-
tality, reinfarction and improve ventricular remodeling 
following MI in patients with reduced left ventricular 
function. Besides their favorable effect on remodeling 
they may also have an antiatherogenic effect. In the ab-
sence of contraindications, ACE inhibitors should 
therefore be initiated early and continued long-term in 
all NSTE-ACS patients unless contraindicated. Their 
efficacy is greatest in patients at high risk, such as pa-
tients with diabetes, hypertension, chronic renal failure, 
signs of heart failure, and depressed left ventricular 
function.
As an alternative to ACE inhibitors, angiotensin II 
receptor blockers can be considered in case of intoler-
ance to ACE inhibitors in patients with heart failure or 
reduced left ventricular function. Finally, aldosterone 
receptor antagonists should be considered in 
NSTE-ACS patients treated with ACE inhibitor and 
-blocker, who have heart failure or reduced left ven-
tricular function. A cardiac rehabilitation program is 
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recommended to achieve the goals of secondary pre-
vention. An exercise stress test to assess functional ca-
pacity is advised within 4–7 weeks after admission for 
NSTE-ACS [35].
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